Ocuphire Pharma (OCUP) News Today → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free OCUP Stock Alerts $1.68 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Ocuphire Pharma’s APX3330 Shows Promise for Diabetic Retinopathy and Pipeline ProgressMay 12, 2024 | finance.yahoo.comOcuphire Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024May 10, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate UpdateMay 6, 2024 | globenewswire.comOcuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual MeetingMay 3, 2024 | globenewswire.comOcuphire Pharma to Present at the Aegis Virtual ConferenceApril 24, 2024 | finance.yahoo.comOcuphire Pharma, Inc. (OCUP)April 22, 2024 | globenewswire.comOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual MeetingApril 11, 2024 | globenewswire.comFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive SurgeryApril 1, 2024 | markets.businessinsider.comOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner ViatrisApril 1, 2024 | globenewswire.comOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner ViatrisMarch 27, 2024 | investing.comOcuphire Pharma COO acquires $4.1k in company stockMarch 26, 2024 | insidertrades.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri Buys 10,000 SharesMarch 21, 2024 | insidertrades.comOcuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath Buys 25,000 SharesMarch 15, 2024 | investorplace.comOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023March 13, 2024 | finance.yahoo.comEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their ForecastsMarch 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy TreatmentMarch 10, 2024 | finance.yahoo.comOcuphire Pharma Full Year 2023 Earnings: Misses ExpectationsMarch 8, 2024 | globenewswire.comOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate UpdateMarch 4, 2024 | msn.comOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?February 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 23, 2024 | globenewswire.comOcuphire Pharma to Present in the BIO CEO & Investor ConferenceFebruary 15, 2024 | globenewswire.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 15, 2024 | uk.investing.comOcuphire Pharma Inc (OCUP)February 14, 2024 | finance.yahoo.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 14, 2024 | globenewswire.comOcuphire Pharma Strengthens Leadership Team with Key AppointmentsFebruary 5, 2024 | finance.yahoo.comOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 ConferenceJanuary 24, 2024 | finance.yahoo.comOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2024 | msn.comOcuphire Pharma files for a $175M mixed securities shelfJanuary 4, 2024 | finance.yahoo.comOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light ConditionsNovember 30, 2023 | markets.businessinsider.comBuy Rating Affirmed for Ocuphire Pharma on Promising Clinical Advancements and Strategic PartnershipsNovember 30, 2023 | msn.comBears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' NowNovember 27, 2023 | msn.comOcuphire announces appointment of Joseph Schachle as chief operating officerNovember 27, 2023 | markets.businessinsider.comOcuphire Pharma Names Joseph Schachle COONovember 27, 2023 | finance.yahoo.comOcuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating OfficerNovember 15, 2023 | benzinga.comOcuphire Pharma Stock (NASDAQ:OCUP) Earnings Dates and Earning CallsNovember 13, 2023 | benzinga.comRecap: Ocuphire Pharma Q3 EarningsNovember 13, 2023 | msn.comOcuphire Pharma GAAP EPS of $0.25, revenue of $11.94MNovember 13, 2023 | finance.yahoo.comOcuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate UpdateNovember 10, 2023 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Ocuphire Pharma, Inc. (NASDAQ:OCUP)?November 4, 2023 | markets.businessinsider.comPromising FDA Feedback and Potential Market Opportunities Drive Buy Rating for Ocuphire PharmaNovember 2, 2023 | finance.yahoo.comOcuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic RetinopathyNovember 1, 2023 | msn.comOcuphire Pharma appoints George Magrath as CEONovember 1, 2023 | finance.yahoo.comOcuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and DirectorOctober 26, 2023 | finance.yahoo.comOcuphire Pharma to Present at AAO 2023 and Eyecelerator Retina ShowcaseOctober 6, 2023 | finance.yahoo.comOcuphire Pharma to Present at Euretina and Retina Society Conferences in OctoberSeptember 28, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Ocuphire Pharma (OCUP)September 28, 2023 | msn.comViatris and Ocuphire Pharma get FDA green light for eye treatmentSeptember 28, 2023 | marketwatch.comOcuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye DropsSeptember 28, 2023 | markets.businessinsider.comBuy Rating for Ocuphire Pharma: FDA Approval of Ryzumvi and Anticipated Developments Boost Stock’s Value Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now OCUP Media Mentions By Week OCUP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUP News Sentiment▼1.870.76▲Average Medical News Sentiment OCUP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUP Articles This Week▼11▲OCUP Articles Average Week Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Greenwich LifeSciences News Lifecore Biomedical News Abeona Therapeutics News Alimera Sciences News Rigel Pharmaceuticals News Veru News Sagimet Biosciences News Context Therapeutics News Cartesian Therapeutics News ProQR Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUP) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
